Kidney replacement therapy, as with any medical therapy, is not without risks. The decision of which therapy and medical device to use should be made by the physician, based on previous experience, and on the individual facts and circumstances of the patient.
NxView™ is contraindicated as the sole method of monitoring a patient during treatment.1
There is no literature demonstrating that one continuous kidney replacement therapy is clinically better than the other.2 The use of anticoagulation is at the discretion of the prescribing physician.
1. NxStage System One User Guide, NC4921 Rev. K 2021-10.
2. D. M. Nash, S. Przech, R. Wald, and D. O’Reilly, “Systematic review and meta-analysis of renal replacement therapy modalities for acute kidney injury in the intensive care unit,” Journal of Critical Care, vol. 41, pp. 138–144, 2017.
CAUTION: Federal law restricts this device to sale by or on the order of a physician.
© 2022 Fresenius Medical Care. All Rights Reserved. Fresenius Medical Care, the triangle logo, NxStage, System One, and NxView are trademarks of Fresenius Medical Care Holdings, Inc. or its affiliated companies. All other trademarks are the property of their respective owners. P/N 105063-01 Rev A 02/2022 APM4546 Rev B
© 2006-2024 Fresenius Medical Care. All Rights Reserved.
